APA (7th ed.) Citation

Ständer, S., Pinter, A., Hougeir, F. G., Guyot, P., Xu, Y., Praestgaard, A. H., . . . Bastian, M. (2026). A Response to "Letter to the Editor Regarding 'Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison'". Dermatology & Therapy, 16(2), 1433. https://doi.org/10.1007/s13555-025-01627-4

Chicago Style (17th ed.) Citation

Ständer, Sonja, et al. "A Response to "Letter to the Editor Regarding 'Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison'"." Dermatology & Therapy 16, no. 2 (2026): 1433. https://doi.org/10.1007/s13555-025-01627-4.

MLA (9th ed.) Citation

Ständer, Sonja, et al. "A Response to "Letter to the Editor Regarding 'Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison'"." Dermatology & Therapy, vol. 16, no. 2, 2026, p. 1433, https://doi.org/10.1007/s13555-025-01627-4.